Decitabine Plus a JAK-Inhibitor
A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 25 patients (estimated)
- Sponsors
- Fred Hutchinson Cancer Research Center
- Tags
- Hypomethylating Agents (HMA), JAK1 Inhibitor, JAK2 Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1651
- NCT Identifier
- NCT04282187
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.